Dubey Arvind Kumar, Nagpal Pran Nath, Chawla Shobhit, Dubey Benu
Dr Dubey's Retina Centre, Gwalior, India.
Indian J Ophthalmol. 2008 Jan-Feb;56(1):23-9. doi: 10.4103/0301-4738.37592.
Many eyes with proliferative diabetic retinopathy (PDR) require vitreous surgery despite complete regression of new vessels with pan retinal laser photocoagulation (PRP). Changes in the vitreous caused by diabetes mellitus and diabetic retinopathy may continue to progress independent of laser regressed status of retinopathy. Diabetic vitreopathy can be an independent manifestation of the disease process.
To examine this concept by studying the long-term behavior of the vitreous in cases of PDR regressed with PRP.
Seventy-four eyes with pure PDR (without clinically evident vitreous traction) showing fundus fluorescein angiography (FFA) proven regression of new vessels following PRP were retrospectively studied out of a total of 1380 eyes photocoagulated between March 2001 and September 2006 for PDR of varying severity. Follow-up was available from one to four years.
Twenty-three percent of eyes showing FFA-proven regression of new vessels with laser required to undergo surgery for indications produced by vitreous traction such as recurrent vitreous hemorrhage, tractional retinal detachment, secondary rhegmatogenous retinal detachment and tractional macular edema within one to four years.
Vitreous changes continued to progress despite regression of PDR in many diabetics. We identifies this as "clinical diabetic vitreopathy" and propose an expanded classification for diabetic retinopathy to signify these changes and to redefine the indications for surgery.
许多患有增殖性糖尿病视网膜病变(PDR)的眼睛,尽管全视网膜激光光凝术(PRP)使新生血管完全消退,但仍需要进行玻璃体手术。糖尿病和糖尿病视网膜病变引起的玻璃体变化可能会继续进展,与视网膜病变的激光消退状态无关。糖尿病性玻璃体病变可能是疾病过程的一种独立表现。
通过研究PRP治疗后PDR患者玻璃体的长期变化情况来验证这一概念。
回顾性研究了74只单纯PDR眼(无临床明显玻璃体牵拉),这些眼睛在2001年3月至2006年9月期间因不同严重程度的PDR接受光凝治疗,共1380只眼,眼底荧光血管造影(FFA)证实PRP后新生血管消退。随访时间为1至4年。
23%的眼睛经FFA证实激光治疗后新生血管消退,但在1至4年内因玻璃体牵拉引起的诸如反复玻璃体出血、牵拉性视网膜脱离、继发性孔源性视网膜脱离和牵拉性黄斑水肿等情况而需要接受手术治疗。
尽管许多糖尿病患者的PDR有所消退,但玻璃体变化仍在继续进展。我们将此确定为“临床糖尿病性玻璃体病变”,并提出对糖尿病视网膜病变进行扩展分类,以表明这些变化并重新定义手术指征。